Spravato® (Esketamine)

What Is Spravato®?

Spravato® (esketamine) is an FDA-approved nasal spray used to treat adults with:
• Treatment-resistant depression (TRD)
• Major depressive disorder (MDD) with suicidal thoughts or behaviors

Spravato® works differently from traditional antidepressants by targeting the brain’s glutamate system, which may lead to faster symptom relief for some patients.

Spravato®

How Is Spravato® Given?

Spravato®

Typical Treatment Schedule

Weeks 1–4

Twice weekly

Weeks 5–8

Once weekly

Maintenance

Every 1–2 weeks as determined by your provider

What To Expect During Treatment

Temporary side effects may include:
These effects usually resolve the same day.
Spravato®

Who Should Not Receive Spravato®

Use with caution if you have a history of psychosis, substance use disorder, liver disease, or are pregnant or breastfeeding. Spravato® is not appropriate for patients with:

History of brain bleeding or aneurysms

Uncontrolled high blood pressure

Uncontrolled high blood pressure

Allergy to esketamine or ketamine

Important Patient Requirements

Must be 18 years or older

Must arrange transportation home

Must remain in the clinic for observation after treatment

Must not drive or operate machinery on treatment days

Do not eat for 2 hours or drink liquids for 30 minutes before treatment

Participation in the FDA-required REMS program is mandatory

Questions?

Please contact Farratti Psychiatry if you have questions or would like to know if Spravato® may be right for you.